Evidence map›Paper›PMID 29636995›Full record

ArticleAmerican journal of cancer research2018

Anticancer efficacies of arsenic disulfide through apoptosis induction, cell cycle arrest, and pro-survival signal inhibition in human breast cancer cells.

Yuxue Zhao, Bo Yuan, Kenji Onda, Kentaro Sugiyama, Sachiko Tanaka, Norio Takagi, Toshihiko Hirano

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. AsCurrent issues in molecular biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Pharmacology, Toxicology, and Rational Application of Cinnabar, Realgar, and Their Formulations.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Yuxue ZhaoDepartment of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Bo YuanDepartment of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Kenji OndaDepartment of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Kentaro SugiyamaDepartment of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Sachiko TanakaDepartment of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Norio TakagiDepartment of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Toshihiko HiranoDepartment of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life SciencesHachioji, Tokyo 192-0392, Japan.
Tokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arsenic disulfide, a major effective component of realgar, has been investigated for its anti-cancer potential and shown to have therapeutic efficacies in hematological and some solid tumors. However, its effect against breast cancer is rarely reported. In this study, we investigated the anti-cancer effects of As

Indexed as

apoptosisArsenic disulfidecell cyclecell viabilityMCF-7MDA-MB-231

Identifiers

PMID29636995
PMCPMC5883090
OpenAlexW2944803460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.